NIH Has Cut Grant Awards by 66% This Year — And the Ones It's Making Look Nothing Like Before

Emily Bruce has applied for 40 grants in five years. She's an assistant professor at the University of Vermont, and she's received exactly three small awards. Right now she's waiting on 11 pending applications, spending more time writing proposals than doing the research those proposals describe. Her situation is not unusual. It is, by the numbers, the new normal.

Through the end of February 2026, the National Institutes of Health awarded 66% fewer grants than it had during the same period in fiscal years 2021 through 2024. The dollar amount dropped 54%. Vermont — one state's window into a national pattern — received $10.3 million for 23 projects halfway through the fiscal year, compared to $41 million for 74 projects throughout all of 2025. The trajectory suggests that when the fiscal year ends, the total will be substantially smaller than any recent year.

These numbers alone would constitute a crisis. But the story underneath the numbers is more complex and, for researchers trying to plan their careers, more consequential. NIH isn't just awarding less money. It's awarding money differently — in ways that restructure who gets funded, how research gets planned, and what the pipeline looks like for the next generation of scientists.

The Lump-Sum Shift

The most structurally significant change isn't the funding cut. It's the move to what NIH internally calls "forward funding" or "lump sum" disbursement.

Under the traditional model, a multi-year grant — say, a five-year R01 — received annual funding increments. Each year, NIH would disburse that year's budget, subject to satisfactory progress and congressional appropriations. The system spread financial risk across time and gave NIH flexibility to adjust funding levels year by year.

Under the emerging model, NIH is pushing full multi-year funding into a single upfront payment. The result is visible in the numbers: the average competitive grant size nearly doubled from $472,000 in the first half of 2025 to over $830,000 by the end of the year. But total grant count plummeted. The math is straightforward — if you front-load five years of funding into one disbursement, each award is larger, but you can make far fewer of them in any given year.

For the researchers who receive these awards, lump-sum funding has advantages. Full upfront funding eliminates the annual anxiety of whether Congress will appropriate enough to sustain out-year commitments. It provides budgeting certainty that annual increments never could. And it insulates ongoing research from future political disruptions — once the money is in the institution's account, it's there.

But the systemic effects are devastating for everyone else. If NIH's annual budget supports, say, 10,000 new and competing awards under the incremental model, the same budget under lump-sum funding might support 3,000 to 4,000. The researchers who land awards are better funded. The researchers who don't land awards — which, in a 66% reduction, is most of them — face a dramatically smaller target.

4,400 Staff Departures and What They Mean

The funding restructuring is happening alongside an institutional upheaval that compounds its effects. Nearly 4,400 NIH staff members have departed since the current administration took office. These aren't abstract headcount reductions. Among the departed are program officers who managed grant portfolios, scientific review officers who organized peer review panels, and grants management specialists who processed awards.

The practical consequences cascade through the system. Fewer program officers means longer response times for pre-submission inquiries — the conversations where experienced PIs learn whether a concept fits a funding institute's priorities before investing months in a full application. Fewer review officers means potential delays in convening study sections. Fewer grants management staff means slower processing of awards that are approved.

Perhaps most significantly, the departures coincide with reports that political appointees have assumed greater roles in grant approval decisions. Under the traditional system, program officers with deep scientific expertise recommended funding based on peer review scores, programmatic balance, and portfolio strategy. The introduction of political oversight into this process adds a layer of review that — regardless of intent — changes the signals that applicants need to read.

The Funding Opportunity Collapse

One of the starkest indicators of NIH's structural shift is the collapse in Notices of Funding Opportunities. By mid-March 2026, NIH had posted just 14 new funding opportunity announcements — compared to 756 during the equivalent period in 2024.

This isn't a temporary delay. The reduction in NOFOs signals a fundamental narrowing of the research agenda. Each funding opportunity announcement represents a scientific area where NIH actively seeks proposals. Fewer NOFOs means fewer defined areas of funded inquiry, which pushes researchers toward an increasingly narrow set of topics that align with the agency's stated priorities.

The practical impact: researchers who study areas not covered by the remaining NOFOs face a choice between pivoting their research programs or waiting — potentially years — for relevant opportunities to reappear. For early-career investigators building research portfolios, that wait may be career-ending.

NIH has also moved all new funding opportunity announcements from the NIH Guide to Grants.gov, a change that disrupts established monitoring workflows. Researchers and grants offices that relied on the NIH Guide's email notifications and search functions must now navigate a different system with different alert mechanisms. The transition is adding operational friction at exactly the moment when identifying opportunities has become more critical.

Who Gets Squeezed

The lump-sum model, combined with overall funding reductions, creates predictable winners and losers.

Established investigators with strong track records are positioned to benefit. When the total number of awards shrinks, review panels and program officers concentrate funding on the applications with the strongest preliminary data, the most experienced teams, and the most compelling track records. Scarcity rewards incumbency.

Early-career researchers face the worst of both worlds. Fewer awards means fiercer competition for the R01s and R21s that establish independent research programs. The K-series career development awards that bridge postdoctoral training and independent funding haven't been immune to cuts. And the collapse in NOFOs reduces the number of entry points into the system.

Small institutions without large endowments or diversified funding sources feel the impact disproportionately. When a major research university loses 30% of its NIH portfolio, it has institutional reserves, philanthropic donors, and industry partnerships to bridge the gap. When a primarily undergraduate institution or a historically Black college loses its one or two NIH grants, it may lose its research capacity entirely.

Certain research fields are more exposed than others. The current administration has signaled priorities in areas like artificial intelligence, biotechnology, and pandemic preparedness. Research that aligns with these priorities has a clearer path to funding. Research in behavioral health, health disparities, social determinants of health, and DEI-related scientific inquiry faces both narrower opportunities and heightened political scrutiny.

What Researchers Should Do Now

The structural changes at NIH aren't temporary disruptions that will reverse when political winds shift. Lump-sum funding, staff reductions, and a narrower research agenda represent institutional choices that will take years to unwind even under a different administration. Researchers need strategies for the system as it exists, not as they wish it were.

Diversify funding sources aggressively. The era when a single NIH R01 could sustain a research program is ending for all but the most fortunate investigators. NSF, DOD, DOE, ARPA-H, and private foundations all fund biomedical and health-related research. State governments are stepping into the gap with their own research funding programs. Building a portfolio across multiple funders reduces dependence on any single agency's political trajectory.

Prioritize program officer contact. With fewer NOFOs and more internal gatekeeping, the pre-submission conversation with program officers has become the single most important step in the application process. Understanding whether your research concept aligns with a program officer's portfolio strategy — and whether that portfolio has funding available — can save months of wasted effort on applications that never had a realistic chance.

Align with stated priorities where scientifically defensible. This is not a suggestion to abandon your research agenda. It is a recognition that framing matters. A health disparities researcher studying diabetes in rural Appalachian communities can frame the same work as "precision public health" or "AI-assisted population health management" without compromising the science. The framing signals alignment with priority areas that are more likely to survive political review.

Build collaborative, multi-institutional proposals. Larger collaborative grants — program projects, center grants, multi-PI R01s — concentrate peer review resources on fewer applications and often carry larger budgets that fit the lump-sum model. They also distribute the administrative burden of federal reporting across multiple institutions, which matters when grants offices are themselves understaffed.

Track the congressional appropriations process. Congress rejected the White House's proposed NIH cuts for FY2026 and restored funding. The appropriations process remains the most direct mechanism for reversing the funding trajectory. Researchers who engage with congressional offices — through professional associations, institutional government relations teams, or direct constituent contact — contribute to the political conditions that determine budget outcomes.

The numbers at NIH are grim, and the structural changes underneath those numbers suggest the grimness will persist. But federal research funding has survived previous contractions, and the researchers who navigated those periods most successfully were the ones who adapted fastest. Platforms like Granted can help researchers identify alternative funding opportunities across federal and private sources — because when the largest funder in the system changes the rules, the researchers who survive are the ones who learn the new rules first.